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Background: Hypoglycaemia is a serious adverse effect of antidiabetic drug therapy. We aimed to determine
incidence rates of hypoglycaemia in type-2 diabetic patients and identify predictors of hypoglycaemia when
treatment is intensified.
Methods: DiaRegis is a prospective German registry that follows 3810 patients with type-2 diabetes referred for
treatment intensification because of insufficient glycaemic control on one or two oral antidiabetic drugs.
Results: Out of a total of 3347 patients with data available for the present analysis 473 (14.1%) presented any
severity hypoglycaemia over a follow-up of 12 months. 0.4% were hospitalized (mean of 1.3±0.6 episodes), 0.1%
needed medical assistance (1.0±0.0), 0.8% needed any help (1.1±0.5) and 10.1% no help (3.4±3.7), and 8.0% had no
specific symptoms (3.6±3.5). Patients with incident hypoglycaemia had longer diabetes duration, higher HbA1c and
a more frequent smoking history; more had co-morbid disease conditions such as coronary artery disease,
peripheral arterial disease, amputation, heart failure, peripheral neuropathy, diabetic retinopathy and clinically
relevant depression at baseline. Multivariable adjusted positive predictors of incident hypoglycaemia over the
follow-up were prior anamnestic hypoglycaemia, retinopathy, depression, insulin use and blood glucose self-
measurement, but not sulfonylurea use as previously reported for anamnestic or recalled hypogylcaemia. On the
contrary, glitazones, DPP-4 inhibitors and GLP-1 analogues were associated with a reduced risk of hypoglycaemia.
Conclusions: Hypoglycaemia is a frequent adverse effect in ambulatory patients when antidiabetic treatment is
intensified. Particular attention is warranted in patients with prior episodes of hypoglycaemia, microvascular disease
such as retinopathy and in patients receiving insulin. On the other hand glitazones, DPP-4 inhibitors and GLP-1
analogues are associated with a reduced risk.Background
Hypoglycaemia is a serious adverse effect while using
antidiabetic pharmacotherapy, irrespective of its severity.
Even in cases of less severe hypoglycaemia a substantial
reduction of cognitive and motor function as well as
hormonal counter regulation is observed [1]. With many
antidiabetic drugs such as sulfonylureas or insulin, inten-
sified blood glucose lowering has been associated with
an increase in the rate of hypoglycaemia [2-4]. It has* Correspondence: diethelm.tschoepe@ruhr-uni-bochum.de
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reproduction in any medium, provided the orbeen suggested that severe hypoglycaemia may simply
be a marker of an increased risk of death and other ad-
verse clinical outcomes rather than a direct cause of
such outcomes [5]. The presence of coexisting condi-
tions could increase a patient’s vulnerability to both se-
vere hypoglycaemia and an adverse clinical outcome in
the absence of a direct causal link between the two [6,7].
To assess the incidence of hypoglycaemia in a cohort
of type-2 diabetic patients in whom treatment was inten-
sified because of insufficient glycaemic control on one or
two oral antidiabetic drugs the prospective registry Dia-
Regis was conducted. The primary objective was to de-
termine the proportion of patients with at least 1 episode
of severe hypoglycaemia (requiring medical help or
hospitalization) within one year. Hypoglycaemia relatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with at least 1 episode of severe, moderate or
mild hypoglycaemia, and to evaluate the number of
hypoglycaemic events per patient, respectively.
Methods
DiaRegis is a prospective, observational, multicenter
registry that included 3810 patients with type-2 diabetes
under the patronage of the foundation “Der herzkranke
Diabetiker” and with sponsorship by AstraZeneca and
Bristol-Myers Squibb [8-12]. It is conducted in accord-
ance with Good Epidemiology Practice (GEP), and ap-
plicable regulatory requirements. The protocol of this
registry was approved by the ethics committee of the
Landesärztekammer Thüringen in Jena, Germany on
March 4th 2009. Patients being enrolled into this registry
provided written informed consent.
Principal design
The principal design characteristic of DiaRegis was that
only patients on one or two oral antidiabetic drugs were
enrolled, in which the treating physician intensified
treatment at the baseline visit. This was done by either
increasing the dose of originally prescribed drugs and /
or by exchanging drugs and / or by adding further drugs
to the previously used ones. These patients were fol-
lowed for 12 months to observe which patients devel-
oped episodes of hypoglycaemia and to determine
patient, disease or treatment characteristics that pre-
dicted the development of hypoglycaemia.
Physicians
Physicians (general practitioners, internists, practitioners
and diabetologists) were selected based on a conditioned
random sampling method. A physician database with
about 9.350 office based physicians treating patients with
type 2 diabetes were approached in writing, and physi-
cians with at least 150 patients with type 2 diabetes
under regular medical care and with a random distribu-
tion across all German regions were asked to participate.
Patients
Patients with type-2 diabetes at an age of at least 40
years on one or two oral antidiabetic drugs (no inject-
ables such as insulin or GLP-1 analogues) were eligible
for inclusion in which the treating physician indicated a
change of therapy to be necessary. The inclusion was
based on the treating physician’s decision but physicians
were asked to consecutively enrol eligible patients.
Those not under regular supervision of the treating
physician for the duration of the study, those with type-
1 diabetes, pregnancy, diabetes secondary to malnutri-
tion, infection or surgery, with maturity onset diabetes
of the young, known cancer or limited life expectancy,acute emergencies, participation in a clinical trial and
patients with further reasons that made it impossible or
highly problematic for the patient to participate and
come to the follow-up visits were excluded from
participation.
Documentation
Patient data at baseline were entered via a secure website
directly into an electronic database at the Stiftung für
Herzinfarktforschung, Ludwigshafen, Germany. At this
stage, they were automatically checked for plausibility and
completeness. For an overview on data collected see the
design and baseline publication [8]. Data from the patient
questionnaire (paper version) which was asked to be com-
pleted by the patient during the visit were transferred to
the CRO appointed. The questionnaires were scanned and
transferred to the Institut für Herzinfarktforschung for
evaluation. All data sets were checked for incorrect data
and corrected if applicable; all corrections are documen-
ted. All data sets are submitted for biostatistic analysis.
Data on co-morbid disease conditions and risk factors
were obtained on an anamnestic basis from the treating
physician but diagnoses were not objectively verified inde-
pendently within this registry. Anamnestic hypoglycaemic
events were collected for the last 12 months prior to in-
clusion based on patient recall. Incident hypoglycaemia
was collected by a patient diary which patients were sup-
posed to show at each physician visit.
Blood glucose monitoring was collected as either “yes”
or “no”. Given that patients indicated to measure BG
themselves, they were asked whether this was done on a
daily, weekly or monthly basis and how often.
Hypoglycaemia definitions
Crude hypoglycaemia rates are reported for anamnes-
tic (any recalled hypoglycaemia within the last 12
months) and incident hypoglycaemia (new episodes of
hypoglycaemia within 12 months of follow-up). In
addition, hypoglycaemia was classified as follows: in case
of severe hypoglycaemia patients were seeking medical
attention or were admitted to hospital because of
hypoglycaemia. In case of moderate hypoglycaemia
patients experienced symptoms of hypoglycaemia and
required assistance from another person (e.g. a relative
or friend), but no attention of a medical professional was
necessary. Mild hypoglycaemia was determined from
blood glucose measurements (<2.22 mmol/l; 40 mg/dl in
any case; 2.22-2.78 or 50 mg/dl in case of symptoms)
and defined as being with or without specific symptoms
but manageable without external help [13,14].
Statistical analysis
For the present analysis on the incidence of
hypoglycaemia a total of 3347 out of 3810 initially enrolled
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the analyses because they were either not alive, had no
data available on hypoglycaemia incidence or were lost to
follow-up.
The statistical analysis was performed using SAS, ver-
sion 9.2 (Cary, North Carolina, U.S.A.). The distribution
of metric variables is described with medians and quar-
tiles or means with standard deviations. All descriptive
statistics are based on available cases. Differences in pa-
tient characteristics, risk factors at baseline and con-
comitant pharmacotherapy were tested using the χ2 or
Mann–Whitney-Wilcoxon Test.
Stepwise multivariable logistic regression analysis was
used to determine independent predictors (adjusted
odds ratios [OR] with 95% confidence intervals) for inci-
dent hypoglycaemia. Variables entered into the model
were identified from univariate analysis, selected for
their potential impact on hypoglycaemia and included
anamnestic hypoglycaemia, age, diabetes duration,
HbA1c, anamnestic heart failure, anamnestic non-
proliferative retinopathy, anamnestic proliferative retin-
opathy, anamnestic coronary artery disease, blood
glucose self-measurement, and anamnestic evidence of
clinically relevant depression. On the other hand periph-
eral arterial disease, amputation, heart failure, and per-






























Without specific symptoms 8.0
Symptomatic, without help 10.1 
Symptomatic with help 0.8
Symptomatic with med. assistance 0.1
Symptomatic with hospitalization 0.4
Figure 1 Anamnestic and incident hypoglycaemia. Patients with anamn
up (n=3347). Legend. *multiple episodes with different episodes captured; *
***only of those with hypoglycaemia.multivariable adjustment. In addition a number of anti-
diabetic drugs such as metformin, sulfonylureas, glucosi-
dase inhibitors, glinides, glitazones, DPP-4 inhibitors,
GLP-1 analogues and insulin use were considered.
Results
Patient characteristics
Patients considered for the present analysis had a me-
dian age of 66.1 (quartiles 51.0-66.1), 46.9% were female,
and had median diabetes duration of 5.6 years (2.9-9.4).
Median HbA1c was 7.4% (6.8-8.2) and 47.6% had an
HbA1c value of at least 7.5%. Patient had a considerable
burden of risk factors (dyslipidemia 63.7%, hypertension
84.7%) and co-morbid disease conditions (coronary ar-
tery disease 18.2%, peripheral neuropathy 13.6%, heart
failure 9.9%, clinically relevant depression 5.3%, and
stroke/TIA 4.6%).
Incidence of hypoglycaemia
Out of a total of 3347 patients 473 (14.1%) had any se-
verity hypoglycaemia over a follow-up of 12 months
(Figure 1). This was higher than the rate documented
for retrospective hypoglycaemia (11.0%) within the 12
months prior to inclusion (but confined to those with a
12 months follow-up). This higher incidence was mostly
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Age (years) 66.8 (57.8-74.1) 65.9 (57.6-72.7) 0.08
Female gender (%) 43.8 47.5 0.14
Diabetes duration
(years)
6.4 (3.0-10.5) 5.5 (2.9-9.2) <0.01
Blood glucose
HbA1c (%) 7.6 (6.8-8.8) 7.4 (6.8-8.1) <0.0001
HbA1c ≥ 7.5% 55.9 46.2 <0.001
FPG (mg/dl) 142 (115–174) 140 (119–168) 0.83




Prior smoker (%) 20.9 14.2 <0.001




Stroke / TIA (%) 5.7 4.5 0.23
PAD (%) 8.6 5.7 <0.05
Amputation (%) 2.3 0.7 <0.001







NPDR (%) 7.4 3.2 <0.0001




Legend. HbA1c, glycosylated haemoglobin A1c; FPG, fasting plasma glucose;
TIA, transitory ischemic attack; PAD, peripheral arterial disease; PPG,
postprandial plasma glucose; (N)PDR, (non) proliferative diabetic retinopathy.
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hypoglycaemia but without a need for help (10.1 vs.
7.6%).
The proportion of patients with at least 1 episode of
severe hypoglycaemia within one year (primary objective;
either requiring medical help or hospitalization) was
0.1+0.4 = 0.5% when only worst episodes were consid-
ered (see table in Figure 1, middle column). Further-
more, the proportion of patients with moderate
hypoglycaemia (requiring external but no medical help)
was 0.7% and 13.0% had mild hypoglycaemia (symptom-
atic 9.7% or asymptomatic 3.3% but without a need for
help) counted as the worst event.
Patients without specific symptoms of hypoglycaemia
reported a mean of 3.6±3.5 episodes similar to patients
with symptoms but without a need for help (mean of
3.4±3.7 episodes). Severe episodes of hypoglycaemia
were reported on average once per year.
An absolute 3.3% of patients had mild hypoglycaemia
without symptoms or a need for help (blood glucose
values <2.22 mmol/l) (see table, middle column in
Figure 1). Overall 10.9% had any degree of symptoms.
Multivariable predictors of incident hypoglycaemia
Patients with incident hypoglycaemia had longer dia-
betes duration (6.4 vs. 5.5 years), higher HbA1c values
(7.6 vs. 7.4%) at baseline and more frequent anamnestic
co-morbid disease conditions such as coronary artery
disease, peripheral arterial disease, amputation, heart
failure, peripheral neuropathy, diabetic retinopathy (both
proliferative and non-proliferative) and clinically relevant
depression (Table 1).
Multivariable adjusted (for variables entered into the
model see methods section) positive predictors of inci-
dent hypoglycaemia over the 12 months follow-up were
prior anamnestic hypoglycaemia (OR 4.05; 95%CI 3.04-
5.39), pre-existent retinopathy (3.27; 1.07-30.02), pre-
existent clinically relevant depression (1.81; 1.14-2.88),
insulin use starting at baseline (2.99; 2.27-3.95) and
blood glucose self-measurement (1.72; 1.23-2.41)
(Figure 2). On the contrary, glitazones (0.55; 0.35-0.86),
DPP-4 inhibitors (0.57; 0.43-0.76) and GLP-1 analogues
(0.48; 0.28-0.81) were associated with a reduced risk of
hypoglycaemia.
Drug treatment as a predictor of incident hypoglycaemia
Table 2 examines the relation between antidiabetic drug
treatment and incident hypoglycaemia more closely.
Amongst patients receiving any type of monotherapy, in-
sulin use was the only positive predictor of incident
hypoglycaemia (OR 6.59; 95%CI 4.43-9.79) while the
reduced rate with DPP-4 inhibitors was statistically only
borderline significant (OR 0.52; 95%CI 0.26-1.03). Insu-
lin use was also predicting hypoglycaemia when used incombination with oral antidiabetic drugs (3.65; 2.92-
4.58). Oral dual combination therapy (0.44; 0.36-0.54),
combination use of metformin with glitazones
(0.46; 0.28-0.83), metformin with DPP-4 inhibitors (0.34;
0.25-0.45) and any OAD with GLP-1 analogues (0.47;
0.30-0.74) were associated with a reduced rate of
hypoglycaemia.
Discussion
The results of this prospective cohort study of patients
with type-2 diabetes suggest that there is a substantial
risk for hypoglycaemia in patients whose treatment is in-
tensified after failure of oral mono or oral dual combin-
ation therapy. This risk is particularly high for episodes
of hypoglycaemia that are symptomatic but where









hypoglycaemia more frequent 
OR (95%CI) 
hypoglycaemia less frequent 
Figure 2 Multivariable predictors of incident hypoglycaemia. Legend. *in any combination at baseline; BG, blood glucose.
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predictors of hypoglycaemia were prior anamnestic
hypoglycaemia (OR 4.05), microvascular disease such as
retinopathy (OR 3.27), clinically relevant depressionTable 2 Pharmacotherapy
Incident hypo 12 months FU
Median (quartiles) or % (n=473








GLP-1 analogues only 0.0
Insulin only 11.0
Dual oral combination therapy 33.1
Met + SU 13.8
Met + Glucosidaseinhibitors 0.2
Met + Glinides 2.1
Met + Glitazones 2.5
Met + DPP-4 inhibitors 12.3
SU + Glitazones 0.4
SU + DPP-4 inhibitors 0.8
OAD + GLP-1 analogues 4.4
OAD + Insulin 31.8
Other combinations 5.3
Legend. DPP-4, dipeptidylpeptidas inhibitors; GLP-1, glucagon-like-peptide 1; OAD, o(OR 1.81) and, with respect to pharmacotherapy insulin
use (OR 2.99). On the contrary, glitazones (OR 0.55),
DPP-4 inhibitors (OR 0.57) and GLP-1 analogues (OR
0.48) were associated with a reduced risk. Although)
No hypo 12 months FU
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hypoglycaemic events [9], there was no significant asso-
ciation between SU use and the risk of hypoglycaemia
during the 12 months FU.
Hypoglycaemia rates
Hypoglycaemia is a frequent adverse effect of antidia-
betic drug treatment. Its definition is however, even
today, still controversial. The practical definition from a
clinical viewpoint of severe (requiring external help for
recovery) and mild (self-treated) hypoglycaemia, as
described in the DCCT [15], has been widely adopted
for epidemiological and clinical use. In 2005 the Ameri-
can Diabetes Association (ADA) defined hypoglycaemia
as an event accompanied by a measured plasma glucose
concentration ≤ 3.9 mmol/l. This plasma glucose thresh-
old was chosen because in non-diabetic people glucose
counter-regulation is activated at this level and
antecedent glucose concentrations of ≤3.9 mmol/l
reduce counter-regulatory responses to subsequent
hypoglycaemia [14]. The DCCT definition does however
not consider asymptomatic biochemical hypoglycaemia
and thresholds for its diagnosis have been suggested to
lie somewhere in between 3.5 and 3.9 mmol/l [13], al-
though the exposure to glucose levels of 3.5–4.0 mmol/l
is likely to be of little clinical significance. Because of
this controversy Swinnen et al. investigated how the
level of blood glucose might impact prevalence rates
reported [14]. They demonstrated that the ADA defin-
ition of ≤ 3.9 mmol/l would result in a high proportion
of hypoglycaemic episodes without a particular clinical
relevance.
Because of the aforementioned controversy on the cor-
rect definition of hypoglycaemia we have chosen to
document the broadest range of possible phenotypes of
hypoglycaemia in our registry including asymptomatic
hypoglycaemia with blood glucose values <2.22 mmol/l
or 40 mg/dl, symptomatic hypoglycaemia with a blood
glucose <2.78 or 50 mg/dl but without a need for help,
symptomatic hypoglycaemia with external lay help, med-
ical help or requiring hospitalization (all irrespective of
blood glucose values). This resulted in an incidence rate
of 14.1%, the majority because of asymptomatic
hypoglycaemia (3.3%) or symptomatic hypoglycaemia
but without the need for help (9.7%). Further we had
0.7% of patients with moderate hypoglycaemia and 0.5%
were classified as being severe. This corresponds to a
rate of 1.2% based on the DCCT definition for severe
hypoglycaemia requiring external help for recovery [15].
Reported rates of severe hypoglycaemic events (as per
DCCT) in clinical studies vary between 0.4% (standard
therapy group in the ADVANCE study [4]) and 3.1% per
year (intensive therapy group in the ACCORD trial) [5].
In UKPDS the rates of major hypoglycaemic episodesper year were 0.7% in the conventional group (mean
HbA1c 7.9%) vs. 1.4% with glibenclamide and 1.8% with
insulin (mean HbA1c 7.0%) [16].
Hypoglycaemia rates were strongly dependent on anti-
diabetic drug treatment as outlined in Figure 2. While
insulin use independently conferred substantial added
risk (OR 2.99; 95%CI 2.27-3.95), GLP-1 analogues, glita-
zones and DPP-4 inhibitors (ORs 0.48, 0.55 and 0.57 re-
spectively) were associated with a reduced risk. This was
also subject of a more detailed analysis in Table 2. The
risk increase with insulin use is compatible with
the results of a number of observational studies such as
the UK Hypoglycaemia Study [17], a retrospective ques-
tionnaire based study from Denmark [18] and a study by
Donnelly et al. [19]. The UK Hypoglycaemia Study [17]
found similar incidence rates of hypoglycaemia in those
recently started on insulin and those treated with sulfo-
nylureas but reported increased rates (25%) in those with
a longer duration of insulin treatment. Rates reported
from Denmark were 16.5% in insulin treated type-2 dia-
betic patients (44 episodes/100 patient years) [18] and
35 episodes/100 patient years of severe hypoglycaemia in
the study by Donnelly et al.[19]. On the other hand, in-
sulin sensitisers (glitazones) and incretin based therapies
(DPP-4 inhibitors, GLP-1 analogues) have been asso-
ciated with a low risk of hypoglycaemia. In the ADOPT
study rates of severe hypoglycaemia requiring help
(0.1%) in patients on rosiglitazone were comparable to
those receiving metformin (0.1%) but substantially lower
than those receiving the SU glibenclamide. Rates of self-
reported symptomatic hypoglycaemia were 10% for met-
formin and rosiglitazone and 38.6% for glibenclamide
[20]. Newer agents based on the incretin system such as
DPP-4 inhibitors and GLP-1 analogues have been asso-
ciated with low risk of hypoglycaemia except when com-
bined with sulfonylureas or insulin [21-23].
Sulfonylureas, which have been associated with a con-
siderable risk of hypoglycaemia were associated with no
added risk in the prospective follow-up, contradicting
analyses we reported for anamnestic hypoglycaemia
prior to treatment escalation at baseline (multivariable
adjusted OR of 2.58; 95%CI 2.03-3.29) [9]. The notion of
an increased risk with sulfonylureas has previously been
reported from the UK Prospective Diabetes Study
(UKPDS) [24] where 31% of subjects reporting mild
hypoglycaemic symptoms with insulin secretagogues in
the first year of use and from the ADOPT study [20]. A
population based study from Germany looking at over
30 000 patients over 4 years found less episodes of se-
vere hypoglycaemia with the newer generation sulfony-
lurea glimepiride (0.86 vs. 5.6 events with glibenclamide
per 1000 patient years) [25]. Against this background
our results are somewhat surprising especially in com-
parison to analyses predicting anamnestic hypoglycaemia
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changes that were introduced over the course of 12
months: 1) sulfonylurea use was reduced between base-
line and the 12 months follow-up from 29.5 to 24.2%, at
least partially also because of hypoglycaemia; 2) oral
monotherapy went down from 68.4% at baseline to
17.8% at the 1 year FU in favour of combined OAD
treatment regimens and insulin / GLP-1 analogue use.
This may have masked hypoglycaemia rates seen with
sulfonylureas as has been shown to be the case in com-
bination with for example DPP-4 inhibitors [26,27].
Finally rates of hypoglycaemia were lower for anam-
nestic or recalled episodes than those prospectively col-
lected in the patient’s diary. There are a number of
potential explanations for this finding beyond treatment
intensification. It appears possible, that is merely
reflects a recall bias and retrospective recording of
hypoglycaemia may have underestimated the back-
ground rate. This is exemplified in individuals with type
1 diabetes who can reliably remember episodes of severe
hypoglycaemia after an interval of one year, but recall of
mild hypoglycaemia becomes unreliable within a week
[28,29]. In people with insulin-treated type 2 diabetes,
recall of severe hypoglycaemia is similarly robust over a
period of one year [30] but the reliability of recall of
mild hypoglycaemia has not been examined and is un-
likely to be preserved. In our study, the increase in
hypoglycaemia was most marked for episodes which
were symptomatic but where no help was required,
which are precisely those which may not have been
recalled at entry to the Diabetes Registry.
Predictors of hypoglycaemia
Out of a number of variables considered to be poten-
tially predictive of subsequent hypoglycaemia such as
anamnestic hypoglycaemia, age, HbA1c, heart failure,
non-proliferative or proliferative retinopathy, coronary
artery disease, blood glucose self-measurement, evidence
of clinically relevant depression and antidiabetic drug
treatment, prior anamnestic hypoglycaemia (OR 4.05),
microvascular disease such as retinopathy (OR 3.27) and
depression (OR 1.81) were identified to be associated
with an increased risk beyond antidiabetic drug treat-
ment as outlined above. On the other hand, the predict-
ive value of a number of variables (except for
microvascular disease) identified in a multivariable ana-
lysis of the ACCORD dataset [31] was not confirmed
which may be related to the selected patient cohort of
the ACCORD study with intensified treatment.
A particular role of anamnestic hypoglycaemia has
previously been reported from intervention studies such
as the Diabetes Control and Complications Trial
(DCCT) and a study reporting on the effects of a teach-
ing programme for intensification of insulin therapywhere a history of severe hypoglycaemia was one of the
main predictors for an increased risk of future severe
hypoglycaemia [32,33]. The finding that depression
is associated with subsequent episodes of (severe)
hypoglycaemia confirms prior data from Finland where
depression was also a significant independent risk factor
for hypoglycaemia [34]. Furthermore, Williams et al.
found in OAD treated type-2 diabetes patients that
hypoglycaemia correlated to significantly lower health
related quality of life that included more anxiety /
depression on a subscale [35].
Blood glucose self-measurement was also predictive
for subsequent hypoglycaemic events, most likely be-
cause of the increased awareness in cases where episodes
were asymptomatic. This sounds like a self-fulfilling
prophecy but is important not only because asymptom-
atic biochemical hypoglycaemia may result in
neurological impairment but also because repeated
hypoglycaemia blunts symptomatic and hormonal
responses to subsequent episodes leading to impaired
awareness of hypoglycaemia, also called hypoglycaemia
associated autonomic failure (HAAF) [36]. These
patients often experience glucose concentrations below
2.0 mmol/l without becoming symptomatic. Further-
more, a number of variables such as glycaemic control,
alcohol, exercise, and age affects and reduces symp-
tomatic and hormonal responses to subsequent
hypoglycaemia [37-41]. Elderly patients also report dif-
ferent symptoms and responses to hypoglycaemia with
less autonomic and more prominent neuroglycopenic
symptoms [42]. In this group, hypoglycaemia can be
misdiagnosed as dementia or neurological events
[43]. We therefore believe that blood glucose self-
measurement not only helps to detect “mild”
hypoglycaemia but also to detect “asymptomatic but se-
vere hypoglycaemia”.
Limitations
Among the strength of the dataset the prospective col-
lection of data on hypoglycaemic events after an adjust-
ment of treatment at baseline has to be noted. After the
switch patients were followed for one year and data on
hypoglycaemia rates, co-morbidity, treatment patterns
and outcomes collected over the follow-up supplement-
ing prior, mostly retrospective database analyses. On the
other hand there are some limitations to the current
analysis deserving consideration: 1) The representative-
ness for the subset of the German population with type-
2 diabetes cannot be assessed. This is because we chose
to recruit patients in primary and specialized care but
not the general population. This is unlikely to affect the
overall conclusion however because it can be assumed
that, after an initial period in which type-2 diabetes may
be unknown (up to 5 years) most patients in Germany
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Hypoglycaemia rates, especially those based on labora-
tory values, are still a matter of debate. This is despite
the ADA giving recommendations for its diagnosis based
on a threshold of ≤ 3.9%, but others have challenged that
the consequence of blood glucose values ≤ 3.9% are clin-
ically irrelevant [13,14]. We have chosen rather low
threshold < 2.22 mmol/ especially for those without
symptoms in the attempt not to overrate the frequency
of these asymptomatic episodes. It may however be chal-
lenged based on the aforementioned. 3) Although data
of the most important known risk marker of severe
hypoglycaemia, impaired hypoglycaemia awareness, was
scored in the DiaRegis [8], the completeness of data was
insufficient to include this risk marker in the analyses. 4)
Finally one might question the selection of variables
considered to identify independent predictors of
hypoglycaemia. While generally the majority of baseline
variables with a significant difference between groups
was considered, those with a high likelihood of interfer-
ence were not selected. On the other hand antidiabetic
pharmacotherapy, with only minor differences at base-
line were included into the model because of their likely
impact on hypoglycaemia rates.
Conclusions
We conclude that hypoglycaemia is a frequent adverse
effect in ambulatory patients when antidiabetic treat-
ment is intensified from oral mono- or dual oral com-
bination therapy. Particular attention is warranted in
patients with prior episodes of hypoglycaemia, micro-
vascular disease such as retinopathy and in patients re-
ceiving insulin. On the other hand, glitazones, DPP-4
inhibitors and GLP-1 analogues are associated with a
reduced risk. Blood glucose self measurement facilitates
the detection of very low blood glucose values that are
less symptomatic than would be expected.
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